Latest Breaking News On - Cardiovascular research foundation technology - Page 1 : comparemela.com

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian mullenChris giordanoJohn frauncesJaved butlerDaniel burkhoffSanjiv shahNasdaq stock marketResearch for the bluhm cardiovascular instituteOrion corporationLifesci advisorsTenax therapeutics incMd northwestern universityTrademark officeCardiovascular research foundation technologyGlobal development

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBrian mullenChris giordanoBaylor scott whiteDaniel burkhoffSanjiv shahJaved butlerJohn frauncesNorthwestern universityResearch for the bluhm cardiovascular instituteCompany secured global commercial rights to levosimendanLifesci advisorsOrion corporationTenax therapeutics incCardiovascular research foundation technologyNasdaq stock market

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - Tenax Therapeutics (NASDAQ:TENX)

First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.

United statesJohn frauncesBaylor scott whiteDaniel burkhoffChris giordanoSanjiv shahJaved butlerBrian mullenCardiovascular research foundation technologyTrademark officeLifesci advisorsOrion corporationCompany secured global commercial rights to levosimendanNorthwestern universityTenax therapeutics incColumbia university

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesChris giordanoSanjivj shahBrian mullenJohn frauncesSanjiv shahResearch for the bluhm cardiovascular instituteCardiovascular research foundation technologyOrion corporationTenax therapeutics incLifesci advisorsNasdaq stock marketCardiovascular research foundationHeart failure therapeuticsHeart failureStone endowed professor

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn frauncesmanaging directorlifesciSanjiv shahChris giordanoSanjivj shahNasdaq stock marketOrion corporationResearch for the bluhm cardiovascular instituteTenax therapeutics incCardiovascular research foundation technologyCardiovascular research foundationHeart failure therapeuticsHeart failureStone endowed professorBluhm cardiovascular instituteNorthwestern university feinberg school